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Abstract
Background: The use of antithrombotic agents and falls are independently associated with an increased
risk of hemorrhagic injury. However, few studies have delineated the risk of fall-related hemorrhagic
complications in persons who are taking antithrombotic therapy. The objective of this study was to
compare the rates of fall-related hemorrhagic injury in hospital in-patients who are taking and not taking
antithrombotic therapy.
Methods: A 4-year retrospective chart review of consecutive patients who fell during admission to a 500-
bed tertiary-care teaching hospital was conducted. Major hemorrhagic injuries including subdural
hematomas and major bleeding/cuts, patients' use of antithrombotic medication (warfarin, aspirin,
clopidogrel and heparin) and their anticoagulation status at the time of their fall were recorded.
Results: A total of 2635 falls in 1861 patients were reviewed. Approximately 10% of falls caused major
hemorrhagic injury. One fall resulted in a subdural hematoma. Persons taking warfarin were less likely to
suffer a fall-related major hemorrhagic injury compared with persons not taking antithrombotic therapy
(warfarin, 6%; no therapy, 11%; p = 0.01). Logistic regression showed that fall-related major hemorrhagic
injury was associated with female gender (odds ratio 1.6; 95% CI 1.3, 2.1), use of aspirin (odds ratio 1.4;
95% CI 1.1, 1.8) and use of clopidogrel (odds ratio 2.2; 95% CI 1.1, 4.8), but not with the use of warfarin
or heparin, or the intensity of anticoagulation.
Conclusions: In this study, compared with persons taking no antithrombotic therapy, those taking
warfarin had lower rates of fall-related hemorrhagic injuries. The absolute rate of the development of fall-
related intracranial hemorrhagic injury such as subdural hematomas was low, even in persons taking
warfarin. These counter-intuitive results may be due to selection bias, and suggest that physicians are very
conservative in selecting patients for warfarin therapy, choosing only those who are sufficiently healthy to
be at much lower than average risk of suffering fall-related hemorrhagic injuries. This phenomenon may
lead to physicians overestimating the potential for fall-related major hemorrhagic injury in persons taking
antithrombotic therapy, with the possible denial of warfarin therapy to many of those who would benefit.
This perception may contribute to the care gap between the number of patients who would theoretically
derive overall benefit from warfarin therapy and those who are actually receiving it.
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Introduction
Antithrombotic agents such as warfarin, aspirin, clopidog-
rel and heparin have proven efficacy and are widely pre-
scribed in the prevention and treatment of many
cardiovascular and cerebrovascular diseases [1-3]. How-
ever, a significant disadvantage of the use of these thera-
pies is an increased incidence of major hemorrhagic
episodes [4]. Compared to younger persons, those over
the age of 65 years are at higher risk of these antithrom-
botic-related complications [5]. Falling, which is also
more common in older persons, can also lead to an
increased risk of hemorrhagic injury [6]. Thus, at least two
studies [7,8] have attempted to delineate the risk of fall-
related hemorrhagic complications in older persons who
are taking antithrombotic therapy. Stein et al [7] exam-
ined 400 consecutive falls in stroke patients admitted to a
rehabilitation center. They found no excess risk of hemor-
rhagic complications in those who were taking warfarin
compared with those who were not. More recently, a
study [8] using decision analytic modeling also deter-
mined that the risk of fall-related hemorrhagic complica-
tions was low, even in those taking warfarin. It concluded
that the risk of falling should not influence the choice of
antithrombotic therapy in older persons with atrial fibril-
lation. However, many clinicians continue to perceive
that older persons who are at increased risk of falling have
an unacceptably high risk of antithrombotic-related
major hemorrhage [9]. Thus, some continue to withhold
antithrombotic therapy in patients who could potentially
derive significant benefit from treatment [10]. The objec-
tive of this retrospective study was to determine whether
there is a difference in hemorrhagic complications in hos-
pital in-patients who fall and are taking antithrombotic
therapy compared with those who are not.
Methods
The protocol was approved by the Ottawa Hospital
Research Ethics Committee and is in compliance with the
Helsinki Declaration. Since implementation of a fall pre-
vention program in 1991, the Ottawa Hospital – Civic
Campus, a 500-bed tertiary care teaching hospital, has
had a formal policy of documenting the pertinent details
of all patient-related falls occurring within the hospital.
Using its dedicated falls database, the records of consecu-
tive falls occurring over a 4-year period (January 1, 1997
to December 31, 2000) were identified. The hospital pol-
icy requires completion of an incident report when
patients fall. Information collected includes the time and
circumstances of the fall, the type of injury (including
head injury) that occurred and a categorization of its
severity, and the need for subsequent follow-up. A mem-
ber of the physician team must eventually review all fall
incident reports, follow-up any significant injury from the
fall and document this information in the hospital record
and incident report.
Hemorrhage (i.e. cuts or bruising) was classified as major
if the immediate attention of a physician was required, or
a clinically apparent intracranial hemorrhage subse-
quently occurred. All other hemorrhage was classified as
minor.
Since patient falls can be seen as a reflection of sub-opti-
mal nursing care, the hospital has adopted a non-punitive
approach to the completion of reports in order to focus on
improving the process that led to the falls. The hospital
recognizes that the value of the falls database is predicated
on maximum completion of incident reports, leading to
the assignment of nurse practitioners dedicated to ensur-
ing the completion of the falls reports. Therefore, it is
unlikely that falls leading to an injury would not be cap-
tured. During the study period, the hospital had no for-
mal policy or guidelines governing the use of
antithrombotic therapy in patients.
For all identified falls, the hospital records of the corre-
sponding in-patient admission were retrieved. Data
extraction from these charts included pertinent patient
demographic information, and the use of antithrombotic
therapy (warfarin, aspirin, clopidogrel and/or heparin) at
the time of the fall. The indications for the use of the par-
ticular antithrombotic therapy were also recorded. Using
computerized laboratory reports, the international nor-
malized ratio (INR) and partial thromboplastin time
(PTT) values that were closest to the time of the fall were
also recorded. Patients' INR values at the time of the fall
were determined as follows:
1. If an INR had been done within 12 hours pre- or post-
fall, this was accepted as the INR value at the time of the
fall. For patients with both 12 hour pre- and post-fall
INRs, these values were averaged.
2. For patients not receiving warfarin, if an INR had not
been done within 12 hours of the fall and the closest tem-
poral INR was within the normal range (INR<1.2), this
was accepted as the INR value occurring at the time of the
fall. If the INR values were abnormal, then the pre- and
post-INR values temporally closest to the time of the fall
were averaged.
3. For persons receiving warfarin at the time of the fall, if
no 12 hour pre- and post fall INRs were available, then the
pre- and post-fall INR values done temporally closest to
the fall were averaged.
4. For persons who did not have an INR while in hospital
and were not receiving warfarin, their charts were
reviewed for possible reasons to have an elevated INR (e.g.
liver disease, coagulapathies). If these were not present,
their INR were deemed to be normal (INR 1.0).Thrombosis Journal 2005, 3:1 http://www.thrombosisjournal.com/content/3/1/1
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For patients taking heparin, an identical approach was
used for determining the PTT values at the time of their
fall.
The discharge summaries, nursing notes and medical
notes of the hospital records were also reviewed for any
immediate and subsequent complications due to the fall
including head trauma, subdural hematoma, intracere-
bral hemorrhage, fractures, major and minor hemorrhage.
Multiple falls by the same person were considered inde-
pendent events. Data extractors were not blinded to the
exposure status of patients or their outcomes.
Statistical analysis was performed using SPSS software ver-
sion 10 (SPSS, Chicago, IL). Chi-square testing was per-
formed to determine the relationship between individual
demographic and clinical factors, and the occurrence of
major hemorrhage. Step-wise forward logistic regression
analysis was then performed with variables that had p-val-
ues < 0.20 on univariate analysis. Given that multiple sta-
tistical comparisons were performed, a p-value < 0.01 was
considered statistically significant.
Results
For the 4-year period, there was a total of 2664 recorded
falls in 1861 patients. Despite numerous attempts, the
corresponding hospital records could not be located for
29 (1.1%) of the falls. Thus, pertinent data were available
and extracted regarding 2635 falls. A significant percent-
age (29.4%) of patients fell more than once during their
admission. The average age of the patients was 71.5 years
(SD 15.2; range 16–104), with most being male (55.2%).
Antithrombotic use persons who fell
Table 1 (see additional file 1) shows the details of the anti-
thrombotic therapy use of the patients who fell. Approxi-
mately 50% of the patients were taking some form of
antithrombotic therapy (warfarin, aspirin, clopidogrel or
heparin) at the time of their fall. Approximately 20% of
patients had INR values that were higher than the normal
range, with a similar number having PTT values outside
the normal range. The most common reason for patients
to be taking warfarin was stroke prevention in atrial fibril-
lation. The most common reasons for taking aspirin and
heparin were prevention of myocardial infarction and
deep vein thrombosis prophylaxis respectively. No
patients with high INRs due to reasons other than warfa-
rin use (e.g. liver failure) were found.
Fall-related injuries
Table 2 (see additional file 2) shows the subsequent inju-
ries due to the falls. Major hemorrhage (i.e. bruising and/
or cuts requiring immediate attention from a physician)
occurred with 10.7% of falls (n = 282). Only one fall
resulted in the development of a subdural hematoma.
This person was an 89 year old male who was taking war-
farin 2 mg and aspirin 81 mg daily (both for stroke pre-
vention in atrial fibrillation) at the same time. His INR
and PTT at the time of the fall were 4.3 and 77 seconds
respectively. It was documented that he suffered head
trauma during the fall. The subdural hematoma was con-
firmed by CT scan of the head, and he subsequently died
from his injuries.
There was also one fall possibly resulting in an intracere-
bral hemorrhage occurring in a 60 year old female. She
also suffered head trauma from her fall, but was not tak-
ing any antithrombotic therapy, and her INR and PTT val-
ues were in the normal range at the time of the fall. She
recovered from this injury, with no apparent sequelae.
The absolute rate of major hemorrhagic injury (i.e sub-
dural hematoma, intracerebral hemorrhage and major
bruising) was lower in persons taking warfarin, compared
with those taking no antithrombotic therapy at all (warfa-
rin, 6.2%; no therapy, 11.3%; p = 0.01). A comparison of
major hemorrhagic injury between those with normal
INR values (INR = <1.3) and those in the therapeutic
range (INR 2–3) showed a strong trend towards fewer
complications in the group with therapeutic INRs (nor-
mal INR, 10.1% (209/2066); INR 2–3, 6.9% (15/218);
odds ratio 0.65, 95% CI; 0.38, 1.13; p = 0.15). A similar
comparison between those with normal INRs and those
with INRs between 3–5, showed no statistical difference
in hemorrhagic complications between the two groups
(normal INRs, 10.1% (209/2066); INR 3–5, 11.4% (9/
79); odds ratio 1.14, 95% CI; 0.56, 2.32; p = 0.70).
Univariate analysis demonstrated a very strong relation-
ship between gender and the occurrence of fall-related
major hemorrhagic injury (i.e. subdural hematomas,
intracerebral hemorrhages and major bruising), with
females being much more likely to suffer one of these
complications compared with males (13.3% (157/1181)
versus 8.7% (126/1454); p < 0.001). Univariate analysis
also showed that there were trends towards an increase in
the occurrence of major hemorrhagic injury with increas-
ing age (p = 0.04), increasing INR values at time of fall (p
= 0.04), and the use of clopidogrel (p = 0.05) or aspirin (p
= 0.20). There was no relationship between major hemor-
rhagic injury with PTT values at time of the fall (p = 0.27),
the use of warfarin (p = 0.42) or the use of heparin (p =
0.62). Similar analyses using major bruising/cuts alone
(and excluding subdural hematomas and intracerebral
hemorrhages) yielded almost identical results. This was
due to the occurrence of only one subdural hematoma
and one intracerebral hemorrhage.
Logistic regression analysis showed that the factors impor-
tant in the development of major hemorrhagic injury dueThrombosis Journal 2005, 3:1 http://www.thrombosisjournal.com/content/3/1/1
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to falls were female gender (odds ratio 1.6; 95% CI 1.3,
2.1), the use of aspirin (odds ratio 1.4; 95% CI 1.1, 1.8)
and the use of clopidogrel (odds ratio 2.2; 95% CI 1.1,
4.8). Of note, increasing age was not an independent risk
factor and there was no interaction between warfarin and
aspirin use.
Repeating the analyses with exclusion of all recurrent falls
in individuals (n = 1861) resulted in no significant differ-
ences in the results reported above.
Of note, fractures occurred in 1.4% of falls (n = 38), with
20 of these being hip fractures.
Discussion
Falling is a common phenomenon in both hospitalized
[11] and community-dwelling [12] older persons, with
many falls leading to major hemorrhagic injury. Many
physicians perceive that the concomitant use of anti-
thrombotic therapy (especially warfarin) increases the
chance of fall-related major hemorrhagic injury. This
study documents the frequency of these injuries due to
falling in hospitalized persons taking antithrombotic
therapy and compares them to those who are not.
Numerous studies [13-15] have shown that the frequency
of hemorrhagic injury is directly proportional to the
intensity of anticoagulation. This study found a signifi-
cant trend (p = 0.04) towards higher intensity anticoagu-
lation status (as measured by INR values) leading to an
increasing chance of the development of fall-related
major hemorrhagic injury. However, when compared to
persons with INRs in the normal range (INR <1.3), there
was no trend suggesting that persons with INRs in the
therapeutic range (INR 2–3) suffer more frequent major
hemorrhagic injury. This suggests that persons with INRs
in the therapeutic range are not at increased risk of suffer-
ing fall-related major hemorrhagic injury, with excess risk
only in those with INRs above the therapeutic range.
The overall results of this study found that persons taking
warfarin were less likely to suffer a fall-related hemor-
rhagic injury, compared to those taking no antithrom-
botic therapy. This counter-intuitive result may be due to
selection bias. That is, physicians were very conservative
in selecting patients for warfarin therapy, choosing only
those who were robust enough to be at very low risk of
suffering a fall-related hemorrhagic injury. Thus, physi-
cians possibly overestimate the potential for major hem-
orrhagic injury in persons taking antithrombotic therapy,
leading to the possible denial of warfarin therapy to many
of those in whom warfarin would otherwise be indicated.
This practice may contribute to the well-documented care
gap between the number of patients who would theoreti-
cally derive overall benefit from warfarin therapy and
those who are actually receiving it. [16,17] However, it
must be remembered that other reasons for this care gap
may exist. For example, since the risk of stroke from atrial
fibrillation more of a long-term, rather than short-term
clinical decision, the in-hospital physicians may have had
a tendency to defer decision-making about anticoagula-
tion to the primary care physicians of these patients.
In this study, only 1 SDH occurred as a result of the more
than 2500 falls. Therefore, it was not possible to perform
meaningful statistical analyses regarding the contributors
to this complication. However, the results confirm that
fall-related subdural hematomas are not common in
older hospitalized persons, even if they are taking anti-
thrombotic agents. That being said, the development of
the single SDH found in this study was almost certainly
related to the concomitant use of warfarin and aspirin,
with an associated INR of greater than 4.0.
The reason(s) for this study finding that female patients
have a greater risk of developing fall-related hemorrhagic
injury is unclear. Age was not a factor as the mean age of
female patients (71.6 years) was similar to male patients
(71.5 years). Also, the percentages of female and male
patients taking warfarin, heparin, clopidogrel or aspirin in
this study were very similar. Other studies [18,19] have
shown that females are more likely to suffer fall-induced
injuries compared with males, though these studies
included non-hemorrhagic injuries such as fractures. The
relationship between gender and fall-related fractures is
explainable by the higher prevalence of osteoporosis in
the older female population.
The use of aspirin or clopidogrel is generally considered to
be less likely to lead to major hemorrhagic injury when
compared with the use of warfarin or heparin. Therefore,
it was surprising to find that there was a weak, but statisti-
cally significant association between fall-related major
hemorrhagic injuries and the use of aspirin or clopidogrel,
but no such relationship with the use of warfarin or
heparin. Again, this result may be due to selection bias,
with physicians favoring the use of aspirin or clopidogrel
over warfarin or heparin in persons who are less healthy
and more prone to serious hemorrhagic injury if they fall.
There are a number of limitations to our study. Due to the
retrospective design, it was not possible to apply standard-
ized definitions and measures when determining the
occurrence, severity and consequences of falls. Also, we
examined the injuries related to hospital-based falls.
Therefore, it is unclear whether our results are generaliza-
ble to other settings. However, the 10.7% rate of major
fall-related hemorrhagic injury (SDH, ICH or major bruis-
ing/cuts) in this study is similar to previous hospital- and
community-based studies [6,12] that found that approxi-Thrombosis Journal 2005, 3:1 http://www.thrombosisjournal.com/content/3/1/1
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mately 5%–10% of falls result in serious injury. In our
database, there were fewer falls causing minor hemor-
rhagic injury compared with major hemorrhagic injury.
This suggests that there was likely underreporting of
minor hemorrhagic injury due to falls. This may have
occurred because, despite hospital policy, nurses were less
inclined to complete incident reports for patients whom
they believed had no potential sequelae to their falls.
Many falls that resulted in little to no injury may not have
been captured. Therefore, the results of our study are likely
to overestimate, rather than underestimate, the rate of
hemorrhagic injury in persons who fall. The methodology
of this study would have been strengthened by reviewing
all hospital admissions over the study period for the risk
of fall-related injuries. The rate of falling in those receiving
and not receiving antithrombotic therapy could then be
determined. If those receiving warfarin were less likely to
fall, then the conclusion that clinicians were reluctant to
prescribe antithrombotic agents (especially warfarin) to
patients they deemed at risk for falls would be strength-
ened. Unfortunately, resource considerations prevented
us from taking this approach. It also would have been
advantageous to have collected further information
regarding potential confounders related to bleeding risk
such as the presence of previous falls or fractures, and the
amount of time patients were in hospital. However, some
of this information was not or could not be reliably col-
lected from the charts. This is because most primary care
physicians often defer to the specialists to make these
decisions. Finally, since there were persons who fell mul-
tiple times, one could argue with our assumption that
each fall was an independent event. However, reanalysis
of the data by including only the first recorded fall from
each individual resulted in no significant changes to the
results.
The study also has an important strength. Not all fall-
related major hemorrhagic injury (especially subdural
hematomas) is identifiable immediately after a fall. We
were able to follow-up the sequelae of falling throughout
the course of the patients' hospital admission. Therefore,
it is unlikely that we failed to identify any serious conse-
quences of falling in our study population.
Conclusion
This study provides evidence that the absolute rate of the
development of fall-related subdural hematomas is low,
even in persons taking warfarin. Also, the lower than
expected rate of fall-related hemorrhagic injury in persons
taking warfarin suggests that physicians may overestimate
the potential for fall-related major hemorrhagic injury in
older persons taking antithrombotic therapy, leading to
an overly conservative approach to assessing the risk of
anticoagulant-related bleeding. This information may
help close the care gap between the number of patients
who would theoretically benefit from anticoagulant ther-
apy and the number that actually receive it. Further study
is necessary to delineate the characteristics of patients who
are at high risk of developing fall-related hemorrhagic
injury when taking antithrombotic therapy.
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